Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezafibrate and medroxyprogesterone acetate for myeloid and lymphoid cancers
ISRCTN99131400Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of bezafibrate and medroxyprogesterone acetate in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 1 more, sponsored by University of Birmingham. Primary endpoints: Safety, Patient compliance and 2 more. Started Oct 2012; status: completed.
02
Drugs
bezafibratemedroxyprogesterone acetate
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mature B-cell lymphoma
Beyond the preview
Go deeper on ISRCTN99131400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99131400.